肝胆期Gd-EOB-DTPA MRI预测基于BCLC算法的HCC标准治疗疗效
本文综述了肝胆期Gd-EOB-DTPA MRI在预测基于BCLC算法的肝细胞癌标准治疗疗效中的作用,重点关注OATP分子背景。肝胆期影像特征可预测治疗疗效并辅助治疗选择;Wnt/β-catenin激活与OATP表达相关,参与肿瘤免疫微环境和化疗反应;瘤周低信号反映微血管侵犯,影响局部至系统治疗的疗效。
要点
- 肝胆期影像特征可在治疗前预测疗效,辅助治疗选择。
- Wnt/β-catenin激活与OATP表达相关,涉及免疫微环境和化疗反应。
- 瘤周低信号提示微血管侵犯,影响局部和系统治疗疗效。
关键影像表现/征象
- 肝胆期影像特征可预测治疗疗效。
- 瘤周低信号反映微血管侵犯。
临床应用与阅片要点
- 阅片时关注肝胆期影像特征以预测治疗疗效。
- 注意瘤周低信号提示微血管侵犯,影响治疗疗效。
局限性
- 为综述,未报告系统检索范围与纳入文献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Recent advances in systemic therapy have had major impacts on treatment strategies for hepatocellular carcinoma (HCC). The 2022 Barcelona Clinic Liver Cancer (BCLC) guidelines incorporate a new section on clinical decision-making for personalized medicine, although the first treatment suggested by the BCLC guidelines is based on solid scientific evidence. More than ever before, the appropriate treatment strategy must be selected prior to the initiation of therapy for HCC. Gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid magnetic resonance imaging (Gd-EOB-DTPA-MRI) is essential for liver imaging and the hepatobiliary phase (HBP) of EOB-MRI reflects the expression of organic anion transporting polypeptide (OATP) transporters. Molecules associated with OATP expression are relevant in the molecular classification of HCC subclasses, and EOB-MRI is becoming increasingly important with advances in the molecular and genetic understanding of HCC. In this review, we describe imaging findings for the pretreatment prediction of response to standard therapies for HCC based on the BCLC algorithm using the HBP of EOB-MRI, with specific attention to the molecular background of OATPs. A more complete understanding of these findings will help radiologists suggest appropriate treatments and clinical follow-ups and could lead to the development of more personalized treatment strategies in the future. CLINICAL RELEVANCE STATEMENT: In the coming era of personalized medicine, HBP of EOB-MRI reflecting molecular and pathological factors could play a predictive role in the therapeutic efficacy of HCC and contribute to treatment selection. KEY POINTS: • Imaging features of hepatobiliary phase predict treatment efficacy prior to therapy and contribute to treatment choice. • Wnt/β-catenin activation associated with organic anion transporting polypeptide expression is involved in the tumor immune microenvironment and chemo-responsiveness. • Peritumoral hypointensity of hepatobiliary phase reflecting microvascular invasion affects the therapeutic efficacy of locoregional to systemic therapy.
引用
- Minamiguchi K, Irizato M, Uchiyama T, et al. Hepatobiliary-phase gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid MRI for pretreatment prediction of efficacy-to-standard-therapies based on Barcelona Clinic Liver Cancer algorithm: an up-to-date review. Eur Radiol. 2023. PMID: 37470828. doi:10.1007/s00330-023-09950-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。